Corbus Pharmaceuticals Holdings (CRBP) Common Equity (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Common Equity for 13 years, with the latest figure at $147.5 million in Q4 2025.

• On a quarterly basis, Common Equity rose 3.56% year-over-year to $147.5 million in Q4 2025; TTM through Dec 2025 was $147.5 million, a 3.56% increase from a year earlier, with the FY2025 full-year figure at $147.5 million, up 3.56% from the prior year.
• Common Equity was $147.5 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $92.1 million in the prior quarter.
• The five-year high for Common Equity was $150.5 million in Q3 2024, with the low at -$6.9 million in Q4 2023.
• Average Common Equity over 5 years is $75.7 million, with a median of $77.3 million recorded in 2021.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 120.93% in 2023, then surged 48136.54% in 2024.
• Over 5 years, Common Equity stood at $69.1 million in 2021, then sank by 52.26% to $33.0 million in 2022, then sank by 120.93% to -$6.9 million in 2023, then surged by 2162.68% to $142.4 million in 2024, then increased by 3.56% to $147.5 million in 2025.
• The last three Common Equity figures came in at $147.5 million (Q4 2025), $92.1 million (Q3 2025), and $111.0 million (Q2 2025), per Business Quant data.